首页 > 最新文献

Hormone Research in Paediatrics最新文献

英文 中文
Potential for Optimization of Growth Hormone Treatment in Children with Growth Hormone Deficiency (GHD), Small for Gestational Age (SGA), and Turner Syndrome (TS) in Germany - Data from the PATRO® Children Study. 德国生长激素缺乏症 (GHD)、小于胎龄 (SGA) 和特纳综合征 (TS) 患儿的生长激素治疗优化潜力--来自 PATRO® 儿童研究的数据。
IF 3.2 3区 医学 Q1 Medicine Pub Date : 2024-04-25 DOI: 10.1159/000539068
Carl-Joachim Partsch, Christof Land, Roland Pfäffle, Karl Otfried Schwab, Heide Sommer
INTRODUCTIONGrowth hormone (GH) treatment in children with growth hormone deficiency (GHD), short children born small for gestational age (SGA), and Turner syndrome (TS) is well established. However, a variety of parameters are still under discussion to achieve optimal growth results and efficiency of GH use in real world treatment.METHODSGerman GH-treatment naïve patients of the PATRO Children database were grouped according to their start of treatment into groups of 3 years from 2007 to 2018. Time trends in age, gender, GH dose, height standard deviation score (SDS), first year growth response, and Index of Responsiveness (IoR) were investigated in children with GHD, short children born SGA, and TS starting GH treatment in the German patient population of the PATRO Children database from 2007 - 2018 to determine specific parameters for GH treatment optimization.RESULTSAll patient groups started GH treatment at a relatively high chronological age (2007 - 2009: GHD 8.33 ± 3.19, SGA 7.32 ± 2.52, TS 8.65 ± 4.39) with a slight but not significant trend towards younger therapy start up to 2016 to 2018 (GHD 8.04 ± 3.36, SGA 6.67 ± 2.65, TS 7.85 ± 3.38). In the GHD and SGA groups female patients were underrepresented compared to male patients (GHD 32.3 %, SGA 43.6 %) with no significant change over the 4 time periods. Patients with GHD started GH treatment at a low dose (0.026 mg/kg/day). In SGA and TS patients GH therapy was started below the registered dose recommendation (0.030 mg/kg/day and 0.0337 mg/kg/day, respectively). In the first year of treatment the mean GH dose was increased moderately (GHD: 0.0307, SGA: 0.0357, TS: 0.0408 mg/kg/day). There was no significant change of GH dosing over time from 2007 - 2018. The IoR was comparable between time-groups for all three diagnoses.DISCUSSIONThis study shows potential for improvement of GH treatment results in GHD, SGA, and TS patients in terms of early dose adjustment and younger age at start of treatment. This is in accordance with important parameters used in prediction models.
导言:生长激素(GH)治疗生长激素缺乏症(GHD)、胎龄不足矮小儿童(SGA)和特纳综合征(TS)已得到广泛认可。然而,为了在实际治疗中达到最佳的生长效果和 GH 使用效率,各种参数仍在讨论之中。方法:将 PATRO 儿童数据库中接受过 GH 治疗的德国患者按照开始治疗的时间分组,从 2007 年到 2018 年每 3 年为一组。研究了2007-2018年PATRO儿童数据库德国患者群体中GHD儿童、SGA出生的矮小儿童和开始接受GH治疗的TS儿童的年龄、性别、GH剂量、身高标准差评分(SDS)、第一年生长反应和反应指数(IoR)的时间趋势,以确定GH治疗优化的具体参数。结果所有患者组开始接受 GH 治疗的年龄都相对较高(2007 - 2009 年:GHD 8.33 ± 3.19,SGA 7.32 ± 2.52,TS 8.65 ± 4.39),到 2016 年至 2018 年,治疗开始年龄有轻微但不显著的年轻化趋势(GHD 8.04 ± 3.36,SGA 6.67 ± 2.65,TS 7.85 ± 3.38)。在GHD和SGA组中,女性患者的比例低于男性患者(GHD为32.3%,SGA为43.6%),4个时间段内没有明显变化。GHD 患者开始接受 GH 治疗时剂量较低(0.026 毫克/千克/天)。SGA 和 TS 患者开始接受 GH 治疗时的剂量低于建议的注册剂量(分别为 0.030 毫克/千克/天和 0.0337 毫克/千克/天)。在治疗的第一年,GH 的平均剂量适度增加(GHD:0.0307 毫克/千克/天,SGA:0.0357 毫克/千克/天,TS:0.0408 毫克/千克/天)。从2007年到2018年,GH剂量没有明显变化。该研究表明,GHD、SGA 和 TS 患者的 GH 治疗效果有可能在早期剂量调整和开始治疗时的年龄降低方面得到改善。这与预测模型中使用的重要参数相符。
{"title":"Potential for Optimization of Growth Hormone Treatment in Children with Growth Hormone Deficiency (GHD), Small for Gestational Age (SGA), and Turner Syndrome (TS) in Germany - Data from the PATRO® Children Study.","authors":"Carl-Joachim Partsch, Christof Land, Roland Pfäffle, Karl Otfried Schwab, Heide Sommer","doi":"10.1159/000539068","DOIUrl":"https://doi.org/10.1159/000539068","url":null,"abstract":"INTRODUCTION\u0000Growth hormone (GH) treatment in children with growth hormone deficiency (GHD), short children born small for gestational age (SGA), and Turner syndrome (TS) is well established. However, a variety of parameters are still under discussion to achieve optimal growth results and efficiency of GH use in real world treatment.\u0000\u0000\u0000METHODS\u0000German GH-treatment naïve patients of the PATRO Children database were grouped according to their start of treatment into groups of 3 years from 2007 to 2018. Time trends in age, gender, GH dose, height standard deviation score (SDS), first year growth response, and Index of Responsiveness (IoR) were investigated in children with GHD, short children born SGA, and TS starting GH treatment in the German patient population of the PATRO Children database from 2007 - 2018 to determine specific parameters for GH treatment optimization.\u0000\u0000\u0000RESULTS\u0000All patient groups started GH treatment at a relatively high chronological age (2007 - 2009: GHD 8.33 ± 3.19, SGA 7.32 ± 2.52, TS 8.65 ± 4.39) with a slight but not significant trend towards younger therapy start up to 2016 to 2018 (GHD 8.04 ± 3.36, SGA 6.67 ± 2.65, TS 7.85 ± 3.38). In the GHD and SGA groups female patients were underrepresented compared to male patients (GHD 32.3 %, SGA 43.6 %) with no significant change over the 4 time periods. Patients with GHD started GH treatment at a low dose (0.026 mg/kg/day). In SGA and TS patients GH therapy was started below the registered dose recommendation (0.030 mg/kg/day and 0.0337 mg/kg/day, respectively). In the first year of treatment the mean GH dose was increased moderately (GHD: 0.0307, SGA: 0.0357, TS: 0.0408 mg/kg/day). There was no significant change of GH dosing over time from 2007 - 2018. The IoR was comparable between time-groups for all three diagnoses.\u0000\u0000\u0000DISCUSSION\u0000This study shows potential for improvement of GH treatment results in GHD, SGA, and TS patients in terms of early dose adjustment and younger age at start of treatment. This is in accordance with important parameters used in prediction models.","PeriodicalId":13025,"journal":{"name":"Hormone Research in Paediatrics","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140654827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric Endocrine Society Statement on Considerations for Use of Teplizumab (Tzield™) in Clinical Practice. 儿科内分泌学会关于在临床实践中使用替普利珠单抗(Tzield™)的注意事项声明。
IF 3.2 3区 医学 Q1 Medicine Pub Date : 2024-04-25 DOI: 10.1159/000538775
Shilpa Mehta, Anna Ryabets-Lienhard, Neha Patel, Emily Breidbart, Ingrid Libman, Michael J. Haller, Kimber M Simmons, Emily K Sims, Linda A. DiMeglio, S. Gitelman, Kurt J. Griffin, Ksenia N Tonyushkina
Teplizumab (TzieldTM, Provention Bio), a monoclonal antibody directed at t-cell marker CD3, is the first medication approved by the FDA to delay progression from Stage 2 to Stage 3 type 1 diabetes (T1D). To date, the overwhelming majority of pediatric endocrinologists do not have experience using immunotherapeutics and seek guidance the use of teplizumab in clinical practice. To address this need, the Pediatric Endocrine Society (PES) Diabetes Special Interest Group (Diabetes SIG) and Drug and Therapeutics Committee assembled a task force to review clinical trial data and solicit expert recommendations on the approach to teplizumab infusions. We present considerations on all aspects of teplizumab administration, utilizing evidence where possible and providing a spectrum of expert opinions on unknown aspects. We discuss patient selection and prescreening, highlighting the safety and considerations for monitoring and treatment of side effects. We propose a schedule of events, a protocol for administration and discuss practice management aspects. We advocate for the need for further long-term systematic surveillance studies to continue evaluating the efficacy and safety of teplizumab.
特普利珠单抗(TzieldTM,Provention Bio)是一种针对 t 细胞标志物 CD3 的单克隆抗体,是美国食品及药物管理局批准的第一种用于延缓 1 型糖尿病(T1D)从 2 期发展到 3 期的药物。迄今为止,绝大多数儿科内分泌专家都没有使用免疫治疗药物的经验,并在临床实践中寻求使用替普利珠单抗的指导。为了满足这一需求,儿科内分泌学会(Pediatric Endocrine Society,PES)糖尿病特别兴趣小组(Diabetes Special Interest Group,Diabetes SIG)和药物与治疗学委员会(Drug and Therapeutics Committee)组建了一个特别工作组来审查临床试验数据,并征求专家对泰普利珠单抗输注方法的建议。我们对替普利珠单抗给药的各个方面进行了考虑,尽可能利用证据,并就未知方面提供了一系列专家意见。我们讨论了患者的选择和预检,强调了副作用监测和治疗的安全性和注意事项。我们提出了活动日程表和用药方案,并讨论了实践管理方面的问题。我们主张有必要开展进一步的长期系统监测研究,以继续评估替普利珠单抗的疗效和安全性。
{"title":"Pediatric Endocrine Society Statement on Considerations for Use of Teplizumab (Tzield™) in Clinical Practice.","authors":"Shilpa Mehta, Anna Ryabets-Lienhard, Neha Patel, Emily Breidbart, Ingrid Libman, Michael J. Haller, Kimber M Simmons, Emily K Sims, Linda A. DiMeglio, S. Gitelman, Kurt J. Griffin, Ksenia N Tonyushkina","doi":"10.1159/000538775","DOIUrl":"https://doi.org/10.1159/000538775","url":null,"abstract":"Teplizumab (TzieldTM, Provention Bio), a monoclonal antibody directed at t-cell marker CD3, is the first medication approved by the FDA to delay progression from Stage 2 to Stage 3 type 1 diabetes (T1D). To date, the overwhelming majority of pediatric endocrinologists do not have experience using immunotherapeutics and seek guidance the use of teplizumab in clinical practice. To address this need, the Pediatric Endocrine Society (PES) Diabetes Special Interest Group (Diabetes SIG) and Drug and Therapeutics Committee assembled a task force to review clinical trial data and solicit expert recommendations on the approach to teplizumab infusions. We present considerations on all aspects of teplizumab administration, utilizing evidence where possible and providing a spectrum of expert opinions on unknown aspects. We discuss patient selection and prescreening, highlighting the safety and considerations for monitoring and treatment of side effects. We propose a schedule of events, a protocol for administration and discuss practice management aspects. We advocate for the need for further long-term systematic surveillance studies to continue evaluating the efficacy and safety of teplizumab.","PeriodicalId":13025,"journal":{"name":"Hormone Research in Paediatrics","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140658647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-Acting Gonadotropin-Releasing Hormone Analogues for Central Precocious Puberty, Including 45-mg 6-month Subcutaneous Leuprolide Acetate: Use for Treatment and Treatment Monitoring. 治疗中枢性性早熟的长效促性腺激素释放激素类似物,包括 45 毫克 6 个月皮下注射醋酸亮丙瑞林:用于治疗和治疗监测。
IF 3.2 3区 医学 Q1 Medicine Pub Date : 2024-04-23 DOI: 10.1159/000539020
Lawrence A. Silverman, Mitchell E. Geffner, Matthew Benson
INTRODUCTIONStudies of gonadotropin-releasing hormone analogues [intramuscular (IM) leuprolide acetate (LA) and triptorelin] for treatment monitoring of central precocious puberty (CPP) demonstrate this approach is effective for confirming pubertal hormone suppression. Herein, we provide new data using subcutaneous LA (SC LA) suggesting similar efficacy for treatment monitoring.METHODSPubMed, Embase, and CINAHL were searched for studies of GnRHa use to monitor treatment of CPP. The titles and the abstracts were reviewed; five studies were selected. Additionally, new unpublished data for SC LA from the original phase 3 trial (primary data published by Klein et al.) were evaluated. Serum LH and leuprolide levels at screening, 1, 4, and 6 hours after the first dose SC LA were analyzed and plotted.RESULTSData from 162 children (155 girls) were evaluated. SC and IM LA produced overlapping median LH concentration curves and peak LH concentrations after the first dose. For IM LA, subsequent doses yielded suppressed peak LH levels (2.7 IU/L [mean]). For SC LA, subsequent doses also resulted in significant suppressed peak LH levels (0.2±0.02 IU/L) and achieved sex-steroid hormone suppression in >98%.CONCLUSIONSCompared to IM LA and triptorelin, long-acting SC LA shows similar burst kinetics and rapid LH rise after the first dose, followed by similar suppression of LH and sex steroids after subsequent doses. Since IM LA and triptorelin have demonstrated usefulness that is comparable to that of traditional GnRH stimulation testing for monitoring CPP, we presume that SC LA may be similarly employed.
简介:对促性腺激素释放激素类似物[肌肉注射(IM)醋酸亮丙瑞林(LA)和曲普瑞林]进行中枢性性早熟(CPP)治疗监测的研究表明,这种方法能有效确认青春期激素抑制。在此,我们提供了使用皮下注射 LA(SC LA)进行治疗监测的新数据,表明这种方法也具有类似的疗效。方法检索了 SpubMed、Embase 和 CINAHL 中有关使用 GnRHa 监测 CPP 治疗的研究。对研究的标题和摘要进行了审阅,从中选出了五项研究。此外,还评估了原始 3 期试验中 SC LA 未发表的新数据(Klein 等人发表的主要数据)。分析并绘制了筛查、首次服用 SC LA 后 1、4 和 6 小时的血清 LH 和亮丙瑞林水平。在第一次给药后,SC LA 和 IM LA 的 LH 浓度曲线中位数和 LH 浓度峰值重叠。对于 IM LA,后续剂量会抑制 LH 峰值水平(2.7 IU/L [平均值])。结论与 IM LA 和曲普瑞林相比,长效 SC LA 表现出相似的爆发动力学和首剂后 LH 的快速上升,随后的剂量对 LH 和性类固醇有相似的抑制作用。由于 IM LA 和曲普瑞林在监测 CPP 方面的作用与传统的 GnRH 刺激试验相当,因此我们推测 SC LA 也可用于监测 CPP。
{"title":"Long-Acting Gonadotropin-Releasing Hormone Analogues for Central Precocious Puberty, Including 45-mg 6-month Subcutaneous Leuprolide Acetate: Use for Treatment and Treatment Monitoring.","authors":"Lawrence A. Silverman, Mitchell E. Geffner, Matthew Benson","doi":"10.1159/000539020","DOIUrl":"https://doi.org/10.1159/000539020","url":null,"abstract":"INTRODUCTION\u0000Studies of gonadotropin-releasing hormone analogues [intramuscular (IM) leuprolide acetate (LA) and triptorelin] for treatment monitoring of central precocious puberty (CPP) demonstrate this approach is effective for confirming pubertal hormone suppression. Herein, we provide new data using subcutaneous LA (SC LA) suggesting similar efficacy for treatment monitoring.\u0000\u0000\u0000METHODS\u0000PubMed, Embase, and CINAHL were searched for studies of GnRHa use to monitor treatment of CPP. The titles and the abstracts were reviewed; five studies were selected. Additionally, new unpublished data for SC LA from the original phase 3 trial (primary data published by Klein et al.) were evaluated. Serum LH and leuprolide levels at screening, 1, 4, and 6 hours after the first dose SC LA were analyzed and plotted.\u0000\u0000\u0000RESULTS\u0000Data from 162 children (155 girls) were evaluated. SC and IM LA produced overlapping median LH concentration curves and peak LH concentrations after the first dose. For IM LA, subsequent doses yielded suppressed peak LH levels (2.7 IU/L [mean]). For SC LA, subsequent doses also resulted in significant suppressed peak LH levels (0.2±0.02 IU/L) and achieved sex-steroid hormone suppression in >98%.\u0000\u0000\u0000CONCLUSIONS\u0000Compared to IM LA and triptorelin, long-acting SC LA shows similar burst kinetics and rapid LH rise after the first dose, followed by similar suppression of LH and sex steroids after subsequent doses. Since IM LA and triptorelin have demonstrated usefulness that is comparable to that of traditional GnRH stimulation testing for monitoring CPP, we presume that SC LA may be similarly employed.","PeriodicalId":13025,"journal":{"name":"Hormone Research in Paediatrics","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140666077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Congenital Hypothyroidism with thyroid in situ: a case report with NKX2-1 and DUOX2 hypomorphic variants. 先天性甲状腺功能减退症伴原位甲状腺:一例NKX2-1和DUOX2低常变异的病例报告。
IF 3.2 3区 医学 Q1 Medicine Pub Date : 2024-04-18 DOI: 10.1159/000538895
Erika Uehara, Naoaki Hori, Kanako Tanase-Nakao, K. Akiba, Hidefumi Sueoka, Keiko Matsubara, Satoshi Narumi
INTRODUCTIONNK2 homeobox 1 (NKX2-1) encodes a transcription factor NKX2-1 that is expressed in the thyroid gland, lung and brain. Dual oxidase 2 (DUOX2) encodes an enzyme which generates hydrogen peroxide and is involved in the thyroid hormone synthesis. Cases of congenital hypothyroidism (CH) with dyshormonogenesis showing two or more genetic variants are increasingly reported. We describe the first case of transient dyshormonogenesis who had experimentally-verified a loss of function NKX2-1 variant and DUOX2 variants.CASE PRESENTATIONThe proband was a 15-year-old female patient with CH who was diagnosed in the frame of newborn screening for CH. She had a mildly elevated serum TSH level (14.56 mU/L), a low free thyroxine level (0.87 ng/dL), and a high thyroglobulin (Tg) level (>800 ng/mL). Ultrasonography revealed goiter. She was followed clinically without levothyroxine treatment, and showed normal growth and development. She had slightly high Tg levels throughout the clinical course. Next-generation sequencing-based genetic analysis revealed that the patient was heterozygous for an NKX2-1 variant (p.Ile228Ser), a nonsense DUOX2 variant (p.[Lys530*;His678Arg]), and a functional DUOX2 polymorphism (p.His678Arg). NKX2-1 p.Ile228Ser showed about 50% reduced residual activity on the Tg-promoter.CONCLUSIONA partial loss-of-function NKX2-1 variant with a monoallelic nonsense DUOX2 variant and a DUOX2 functional polymorphism can cause transient CH with high serum Tg levels.
简介NK2同源框1(NKX2-1)编码一种转录因子NKX2-1,该因子在甲状腺、肺和大脑中表达。双氧化酶2(DUOX2)编码一种产生过氧化氢的酶,参与甲状腺激素的合成。先天性甲状腺功能减退症(CH)伴有两种或两种以上基因变异的激素生成障碍病例的报道越来越多。我们描述了第一例经实验证实存在功能缺失的NKX2-1变体和DUOX2变体的一过性甲状腺激素生成障碍病例。她的血清促甲状腺激素水平轻度升高(14.56 mU/L),游离甲状腺素水平低(0.87 ng/dL),甲状腺球蛋白(Tg)水平高(>800 ng/mL)。超声波检查显示她患有甲状腺肿。在没有接受左甲状腺素治疗的情况下,对她进行了临床随访,结果显示她的生长发育正常。在整个临床过程中,她的Tg水平一直略高。基于下一代测序的基因分析表明,该患者是NKX2-1变体(p.Ile228Ser)、无义DUOX2变体(p.[Lys530*;His678Arg])和功能性DUOX2多态性(p.His678Arg)的杂合子。NKX2-1 p.Ile228Ser在Tg启动子上的残余活性降低了约50%。结论部分功能缺失的NKX2-1变体与单倍无义DUOX2变体和DUOX2功能性多态性可导致血清Tg水平较高的一过性CH。
{"title":"Congenital Hypothyroidism with thyroid in situ: a case report with NKX2-1 and DUOX2 hypomorphic variants.","authors":"Erika Uehara, Naoaki Hori, Kanako Tanase-Nakao, K. Akiba, Hidefumi Sueoka, Keiko Matsubara, Satoshi Narumi","doi":"10.1159/000538895","DOIUrl":"https://doi.org/10.1159/000538895","url":null,"abstract":"INTRODUCTION\u0000NK2 homeobox 1 (NKX2-1) encodes a transcription factor NKX2-1 that is expressed in the thyroid gland, lung and brain. Dual oxidase 2 (DUOX2) encodes an enzyme which generates hydrogen peroxide and is involved in the thyroid hormone synthesis. Cases of congenital hypothyroidism (CH) with dyshormonogenesis showing two or more genetic variants are increasingly reported. We describe the first case of transient dyshormonogenesis who had experimentally-verified a loss of function NKX2-1 variant and DUOX2 variants.\u0000\u0000\u0000CASE PRESENTATION\u0000The proband was a 15-year-old female patient with CH who was diagnosed in the frame of newborn screening for CH. She had a mildly elevated serum TSH level (14.56 mU/L), a low free thyroxine level (0.87 ng/dL), and a high thyroglobulin (Tg) level (>800 ng/mL). Ultrasonography revealed goiter. She was followed clinically without levothyroxine treatment, and showed normal growth and development. She had slightly high Tg levels throughout the clinical course. Next-generation sequencing-based genetic analysis revealed that the patient was heterozygous for an NKX2-1 variant (p.Ile228Ser), a nonsense DUOX2 variant (p.[Lys530*;His678Arg]), and a functional DUOX2 polymorphism (p.His678Arg). NKX2-1 p.Ile228Ser showed about 50% reduced residual activity on the Tg-promoter.\u0000\u0000\u0000CONCLUSION\u0000A partial loss-of-function NKX2-1 variant with a monoallelic nonsense DUOX2 variant and a DUOX2 functional polymorphism can cause transient CH with high serum Tg levels.","PeriodicalId":13025,"journal":{"name":"Hormone Research in Paediatrics","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140688534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Growth hormone therapy: Comparison of short- and long-term outcomes between children with Growth Hormone Deficiency and Small for Gestational Age. 生长激素疗法:生长激素缺乏症和小于胎龄儿童的短期和长期疗效比较。
IF 3.2 3区 医学 Q1 Medicine Pub Date : 2024-04-18 DOI: 10.1159/000538798
Andreas Gleiss, A. Raimann, Florentina Haufler, D. Ertl, S. Sagmeister, Gabriele Hartmann
Introduction Direct comparisons of both short-term and long-term auxological outcome of growth hormone therapy (GHT) between growth hormone deficiency (GHD) and small for gestational age (SGA) are scarce. Methods 103 patients with GHD and 53 patients with SGA treated at our tertiary center were investigated. Short-term and long-term outcomes were compared between these groups using multi-variable linear regression models with adjustment for age, sex and height at therapy start, also allowing for sex-specific group comparisons. Results Mean delta height standard deviation scores (SDS) after 1 year of treatment was significantly higher in GHD (0.90, CI 0.82 to 0.99) compared to SGA (0.67, C I 0.54 to 0.79)(p= 0.003) with no sex difference. As expected, the mean increase in height SDS at final height (FH) was significantly higher in GHD (2.21, CI 2.00 to 2.42) compared to SGA (1.05, CI 0.75 to 1.35)(p<0.001), leading to a target height corrected FH of -0.39 SDS (CI -0.62 to -0.15) in GHD and -1.22 SDS (CI-1.57 to -0.87) in SGA ( p<0.001). Girls with GHD had a better long-term outcome, as did boys with SGA when compared to the respective opposite sex. The cut-off of delta height of 0.5 SDS during the first year had a low sensitivity to detect long-term non-responders. We found a relation between short-term and long-term outcome in GHD, but not in SGA (adjusted R2 = 0.66 vs. 0.01). Conclusion In contrast to GHD, we observed practically no relationship between 1st-year and long-term outcome in SGA patients treated with GH.
导言:生长激素缺乏症(GHD)和小于胎龄儿(SGA)之间生长激素治疗(GHT)的短期和长期辅助治疗效果的直接比较很少见。方法 调查了在我们的三级中心接受治疗的 103 名 GHD 患者和 53 名 SGA 患者。采用多变量线性回归模型对这两组患者的短期和长期疗效进行了比较,并对开始治疗时的年龄、性别和身高进行了调整,还对特定性别组进行了比较。结果 GHD(0.90,CI 0.82 至 0.99)治疗 1 年后的平均身高标准偏差(SDS)显著高于 SGA(0.67,C I 0.54 至 0.79)(p= 0.003),且无性别差异。不出所料,与 SGA(1.05,CI 0.75 至 1.35)(p<0.001)相比,GHD 最终身高(FH)的平均身高 SDS 增长率(2.21,CI 2.00 至 2.42)明显更高,导致 GHD 的目标身高校正 FH 为 -0.39 SDS(CI -0.62 至 -0.15),SGA 为 -1.22 SDS(CI-1.57 至 -0.87)(p<0.001)。与异性相比,GHD女孩的长期预后较好,SGA男孩也是如此。第一年的身高δ值为 0.5 SDS 时,检测长期无应答者的灵敏度较低。我们发现 GHD 患者的短期结果与长期结果之间存在关系,而 SGA 患者则没有这种关系(调整后的 R2 = 0.66 vs. 0.01)。结论 与 GHD 相反,我们发现接受 GH 治疗的 SGA 患者第一年的疗效与长期疗效之间几乎没有关系。
{"title":"Growth hormone therapy: Comparison of short- and long-term outcomes between children with Growth Hormone Deficiency and Small for Gestational Age.","authors":"Andreas Gleiss, A. Raimann, Florentina Haufler, D. Ertl, S. Sagmeister, Gabriele Hartmann","doi":"10.1159/000538798","DOIUrl":"https://doi.org/10.1159/000538798","url":null,"abstract":"Introduction Direct comparisons of both short-term and long-term auxological outcome of growth hormone therapy (GHT) between growth hormone deficiency (GHD) and small for gestational age (SGA) are scarce. Methods 103 patients with GHD and 53 patients with SGA treated at our tertiary center were investigated. Short-term and long-term outcomes were compared between these groups using multi-variable linear regression models with adjustment for age, sex and height at therapy start, also allowing for sex-specific group comparisons. Results Mean delta height standard deviation scores (SDS) after 1 year of treatment was significantly higher in GHD (0.90, CI 0.82 to 0.99) compared to SGA (0.67, C I 0.54 to 0.79)(p= 0.003) with no sex difference. As expected, the mean increase in height SDS at final height (FH) was significantly higher in GHD (2.21, CI 2.00 to 2.42) compared to SGA (1.05, CI 0.75 to 1.35)(p<0.001), leading to a target height corrected FH of -0.39 SDS (CI -0.62 to -0.15) in GHD and -1.22 SDS (CI-1.57 to -0.87) in SGA ( p<0.001). Girls with GHD had a better long-term outcome, as did boys with SGA when compared to the respective opposite sex. The cut-off of delta height of 0.5 SDS during the first year had a low sensitivity to detect long-term non-responders. We found a relation between short-term and long-term outcome in GHD, but not in SGA (adjusted R2 = 0.66 vs. 0.01). Conclusion In contrast to GHD, we observed practically no relationship between 1st-year and long-term outcome in SGA patients treated with GH.","PeriodicalId":13025,"journal":{"name":"Hormone Research in Paediatrics","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140687251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic Conundrum of a Sertoli Cell Tumor in a 2-Year-Old Girl with Peripheral Precocious Puberty and a Café-Au-Lait Macule: A Case Report. 患有外周性早熟和咖啡斑的 2 岁女孩的 Sertoli 细胞瘤诊断难题:病例报告。
IF 3.2 3区 医学 Q1 Medicine Pub Date : 2024-04-16 DOI: 10.1159/000538945
Lauren A Ray, Deborah F. Billmire, Michael J Ferguson, Erica A Eugster
INTRODUCTIONOvarian Sertoli cell tumors represent a subset of sex cord-stromal tumors and are exceedingly rare in prepubertal children. Here we report a girl with vaginal bleeding due to a Sertoli cell tumor who was originally thought to have McCune-Albright syndrome (MAS).CASE PRESENTATIONA previously healthy girl presented at age two years six months with breast development and vaginal bleeding. On exam, she had Tanner 4 breasts, Tanner 1 pubic hair, estrogenized vaginal mucosa, and a café-au-lait macule. Laboratory studies revealed an elevated estradiol with suppressed gonadotropins and negative tumor markers. Her bone age was advanced by more than three years. Pelvic ultrasound (US) revealed an enlarged uterus and a slightly larger left compared to right ovary. She was started on tamoxifen for presumed MAS. A repeat pelvic US one month later showed a heterogenous mass in the left ovary which was subsequently resected. Pathology revealed a Sertoli cell tumor, lipid-rich variant. Germline sequencing revealed a pathogenic STK11 variant, diagnostic for Peutz-Jeghers syndrome (PJS).CONCLUSIONThe findings in our patient were strikingly similar to those encountered in MAS. To our knowledge, our patient is the youngest ever reported to present with precocious puberty due to a Sertoli cell tumor in the setting of PJS.
导言卵巢Sertoli细胞瘤是性索间质肿瘤的一个分支,在青春期前的儿童中极为罕见。在此,我们报告了一名因 Sertoli 细胞瘤导致阴道出血的女孩,她原本被认为患有麦库那-阿尔布莱特综合征(McCune-Albright Syndrome,MAS)。病例介绍 一名原本健康的女孩在两岁六个月时出现乳房发育和阴道出血。经检查,她的乳房为坦那4型,阴毛为坦那1型,阴道粘膜雌激素化,并有咖啡色黄褐斑。实验室检查显示雌二醇升高,促性腺激素受到抑制,肿瘤标志物阴性。她的骨龄提前了三年多。盆腔超声(US)显示子宫增大,左侧卵巢比右侧卵巢稍大。她开始服用他莫昔芬来治疗假定的 MAS。一个月后,她再次接受盆腔超声检查,发现左侧卵巢有一个异质肿块,随后将其切除。病理结果显示,这是一种富含脂质的变异型 Sertoli 细胞肿瘤。种系测序发现了一个STK11致病变体,可诊断为Peutz-Jeghers综合征(PJS)。据我们所知,我们的患者是史上最年轻的因Sertoli细胞肿瘤而导致性早熟的PJS患者。
{"title":"Diagnostic Conundrum of a Sertoli Cell Tumor in a 2-Year-Old Girl with Peripheral Precocious Puberty and a Café-Au-Lait Macule: A Case Report.","authors":"Lauren A Ray, Deborah F. Billmire, Michael J Ferguson, Erica A Eugster","doi":"10.1159/000538945","DOIUrl":"https://doi.org/10.1159/000538945","url":null,"abstract":"INTRODUCTION\u0000Ovarian Sertoli cell tumors represent a subset of sex cord-stromal tumors and are exceedingly rare in prepubertal children. Here we report a girl with vaginal bleeding due to a Sertoli cell tumor who was originally thought to have McCune-Albright syndrome (MAS).\u0000\u0000\u0000CASE PRESENTATION\u0000A previously healthy girl presented at age two years six months with breast development and vaginal bleeding. On exam, she had Tanner 4 breasts, Tanner 1 pubic hair, estrogenized vaginal mucosa, and a café-au-lait macule. Laboratory studies revealed an elevated estradiol with suppressed gonadotropins and negative tumor markers. Her bone age was advanced by more than three years. Pelvic ultrasound (US) revealed an enlarged uterus and a slightly larger left compared to right ovary. She was started on tamoxifen for presumed MAS. A repeat pelvic US one month later showed a heterogenous mass in the left ovary which was subsequently resected. Pathology revealed a Sertoli cell tumor, lipid-rich variant. Germline sequencing revealed a pathogenic STK11 variant, diagnostic for Peutz-Jeghers syndrome (PJS).\u0000\u0000\u0000CONCLUSION\u0000The findings in our patient were strikingly similar to those encountered in MAS. To our knowledge, our patient is the youngest ever reported to present with precocious puberty due to a Sertoli cell tumor in the setting of PJS.","PeriodicalId":13025,"journal":{"name":"Hormone Research in Paediatrics","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140698353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The digital-human interface: an essential combination for clinical progress. 数字-人机界面:临床进步的必要组合。
IF 3.2 3区 医学 Q1 Medicine Pub Date : 2024-04-13 DOI: 10.1159/000538896
Martin O Savage
{"title":"The digital-human interface: an essential combination for clinical progress.","authors":"Martin O Savage","doi":"10.1159/000538896","DOIUrl":"https://doi.org/10.1159/000538896","url":null,"abstract":"","PeriodicalId":13025,"journal":{"name":"Hormone Research in Paediatrics","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140708280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A new variant in the GATA6 gene associated with tracheoesophageal fistula, pulmonary vein stenosis and neonatal diabetes. 与气管食管瘘、肺静脉狭窄和新生儿糖尿病有关的 GATA6 基因新变异。
IF 3.2 3区 医学 Q1 Medicine Pub Date : 2024-04-04 DOI: 10.1159/000536621
Flaminia Pugnaloni, L. Martini, D. D. De Rose, F. Landolfo, P. Giliberti, Rosario Ruta, Antonio Novelli, N. Rapini, Fabrizio Barbetti, Alessandra Toscano, A. Conforti, Pietro Bagolan, I. Capolupo, A. Dotta
INTRODUCTIONGATA6 is a gene that encodes a transcription factor with a key role in the development of several organ systems, including the development of the pancreas. It is associated with neonatal diabetes but also with other extra-pancreatic anomalies.CASE PRESENTATIONThis report describes the association of tracheoesophageal fistula (TEF), pulmonary vein stenosis (PVS), and neonatal diabetes caused by a novel mutation of the GATA6 gene in a small-for-gestational-age male neonate born at 32 weeks of gestation. Next-Generation Sequencing revealed the novel heterozygous variant c.1502C>G in the GATA6 gene, which determines the introduction of the premature stop codon p.Ser501Ter at the protein level. This de novo nonsense variant was not detected in the analyzed parental DNA samples and has not been previously described in the literature. At about two months of life, a PVS was suspected. The PVS progressively increased with the development of an intramural component, resulting in severe postcapillary pulmonary hypertension. The child died at about 4 months of life.CONCLUSIONTEF can be associated with GATA6 variants. In the case of neonatal diabetes and TEF, neonatologists should be aware of this association and should also investigate the child for complex congenital heart disorders, such as in our case, with a cardiac computed tomography.
简介GATA6 是一个编码转录因子的基因,在包括胰腺发育在内的多个器官系统的发育过程中起着关键作用。本报告描述了一名妊娠 32 周出生的小胎龄男性新生儿因 GATA6 基因的新型突变导致气管食管瘘 (TEF)、肺静脉狭窄 (PVS) 和新生儿糖尿病。下一代测序发现了 GATA6 基因中的新型杂合变异 c.1502C>G,它决定了在蛋白质水平上引入过早终止密码子 p.Ser501Ter。在分析的亲代 DNA 样本中没有检测到这一新的无义变异,以前的文献中也没有描述过。出生两个月左右时,怀疑出现了 PVS。随着壁内成分的发展,PVS逐渐加重,导致严重的毛细血管后肺动脉高压。该患儿在出生约 4 个月时死亡。在新生儿糖尿病和 TEF 的病例中,新生儿科医生应意识到这种关联性,并通过心脏计算机断层扫描检查患儿是否患有复杂的先天性心脏病,如我们的病例。
{"title":"A new variant in the GATA6 gene associated with tracheoesophageal fistula, pulmonary vein stenosis and neonatal diabetes.","authors":"Flaminia Pugnaloni, L. Martini, D. D. De Rose, F. Landolfo, P. Giliberti, Rosario Ruta, Antonio Novelli, N. Rapini, Fabrizio Barbetti, Alessandra Toscano, A. Conforti, Pietro Bagolan, I. Capolupo, A. Dotta","doi":"10.1159/000536621","DOIUrl":"https://doi.org/10.1159/000536621","url":null,"abstract":"INTRODUCTION\u0000GATA6 is a gene that encodes a transcription factor with a key role in the development of several organ systems, including the development of the pancreas. It is associated with neonatal diabetes but also with other extra-pancreatic anomalies.\u0000\u0000\u0000CASE PRESENTATION\u0000This report describes the association of tracheoesophageal fistula (TEF), pulmonary vein stenosis (PVS), and neonatal diabetes caused by a novel mutation of the GATA6 gene in a small-for-gestational-age male neonate born at 32 weeks of gestation. Next-Generation Sequencing revealed the novel heterozygous variant c.1502C>G in the GATA6 gene, which determines the introduction of the premature stop codon p.Ser501Ter at the protein level. This de novo nonsense variant was not detected in the analyzed parental DNA samples and has not been previously described in the literature. At about two months of life, a PVS was suspected. The PVS progressively increased with the development of an intramural component, resulting in severe postcapillary pulmonary hypertension. The child died at about 4 months of life.\u0000\u0000\u0000CONCLUSION\u0000TEF can be associated with GATA6 variants. In the case of neonatal diabetes and TEF, neonatologists should be aware of this association and should also investigate the child for complex congenital heart disorders, such as in our case, with a cardiac computed tomography.","PeriodicalId":13025,"journal":{"name":"Hormone Research in Paediatrics","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140744907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ERRγ1 and Aromatase Expression in Human Placental Tissues from Term Deliveries of Large for Gestational Age (LGA) Newborns. ERRγ1和芳香化酶在足月分娩的大妊娠期(LGA)新生儿的人类胎盘组织中的表达。
IF 3.2 3区 医学 Q1 Medicine Pub Date : 2024-03-26 DOI: 10.1159/000538284
Marcos Abdul Palligas, Cristina Patricia Nemer, Claudia Monica Cannizzaro, Maria Sonia Baquedano, Alicia Belgorosky, Nora Saraco

Introduction: Being born either large (LGA) or small for gestational age (SGA) has been associated with an increased risk of developing metabolic syndrome in adulthood. However, the mechanism underlying this early programming remained unclear. Estrogen-related receptor gamma (ERRγ) is an orphan nuclear receptor with a high expression in human placenta, particularly ERRγ1. ERRγ has been proposed to play a central role in controlling genes involved in energy metabolism. In placenta, ERRγ1 acts as an oxygen-responsive transcription factor regulating aromatase (Aro) expression during trophoblast differentiation. Aromatase is an enzyme that catalyzes the synthesis of estrogens from androgens and is located in the syncytiotrophoblast. An adequate estrogen-androgen balance is required for normal pregnancy progression. Our aim was to analyze ERRγ1 and Aro mRNA in human placenta from term LGA newborns. We propose that ERRγ1 and CYP19A1 expressions in human placenta from LGA newborns are impaired, which would modify fetal programming of LGA newborns, since an imbalance in intrauterine estrogen-androgen ratio would be occurred Methods: Total RNA was obtained from placental tissues of LGA (GA: 39-41 weeks, n=8) and adequate for gestational age (AGA; 39-40 weeks, n=10) newborns. ERRγ1 and Aro mRNA variants were analyzed by RT2-PCR. Primers for Aro analysis were specific for Total aromatase (TotalAro) binding in exons 2-3 and for Active aromatase (ActAro) in exons 9-10. Aro protein was analyzed by Western-blot.

Results: ERRγ1 mRNA was significantly higher in LGA compare to AGA. TotalAro mRNA was significantly lower in LGA in comparison with AGA control. Similar results with Aro protein. In contrast ActAro/TotalAro ratio was higher in LGA compared to the AGA control.

Conclusions: High expression of ERRγ1 as well as ActAro/TotalAro ratio in LGA suggests that ERRγ1 is involved in ActAro variant expression and hence disrupted estrogen-androgen balance in the intrauterine environment. We propose that dysregulation of ERRγ1 in placenta might modify the estrogen-androgen balance in the intrauterine environment in LGA newborns, possibly representing one of the key factors in the regulation of fetal programming.

导言:出生时胎儿过大(LGA)或胎儿过小(SGA)与成年后患代谢综合征的风险增加有关。然而,这种早期规划的机制仍不清楚。雌激素相关受体γ(ERRγ)是一种孤儿核受体,在人类胎盘中高表达,尤其是ERRγ1。ERRγ被认为在控制参与能量代谢的基因方面发挥着核心作用。在胎盘中,ERRγ1作为氧反应转录因子,在滋养层分化过程中调节芳香化酶(Aro)的表达。芳香化酶是一种催化雄激素合成雌激素的酶,位于合体滋养细胞中。正常的妊娠过程需要雌激素和雄激素的充分平衡。我们的目的是分析足月 LGA 新生儿胎盘中的ERRγ1 和 Aro mRNA。我们认为ERRγ1和CYP19A1在LGA新生儿胎盘中的表达受损,这将改变LGA新生儿的胎儿发育过程,因为宫内雌激素和雄激素的比例失调将会发生:从 LGA(GA:39-41 周,n=8)和足月(AGA:39-40 周,n=10)新生儿的胎盘组织中获取总 RNA。ERRγ1和Aro mRNA变异通过RT2-PCR进行分析。分析 Aro 的引物对 2-3 号外显子中的总芳香化酶(TotalAro)和 9-10 号外显子中的活性芳香化酶(ActAro)具有特异性。通过 Western-blot 对 Aro 蛋白进行分析:结果:ERRγ1 mRNA在LGA中明显高于AGA。总Aro mRNA在LGA中明显低于AGA对照组。Aro 蛋白也有类似结果。相反,与AGA对照组相比,LGA的ActAro/TotalAro比值更高:结论:LGA中ERRγ1的高表达以及ActAro/TotalAro比值表明,ERRγ1参与了ActAro变体的表达,从而破坏了宫内环境中雌激素与雄激素的平衡。我们认为,胎盘中ERRγ1的失调可能会改变LGA新生儿宫内环境中雌激素和雄激素的平衡,这可能是调控胎儿编程的关键因素之一。
{"title":"ERRγ1 and Aromatase Expression in Human Placental Tissues from Term Deliveries of Large for Gestational Age (LGA) Newborns.","authors":"Marcos Abdul Palligas, Cristina Patricia Nemer, Claudia Monica Cannizzaro, Maria Sonia Baquedano, Alicia Belgorosky, Nora Saraco","doi":"10.1159/000538284","DOIUrl":"https://doi.org/10.1159/000538284","url":null,"abstract":"<p><strong>Introduction: </strong>Being born either large (LGA) or small for gestational age (SGA) has been associated with an increased risk of developing metabolic syndrome in adulthood. However, the mechanism underlying this early programming remained unclear. Estrogen-related receptor gamma (ERRγ) is an orphan nuclear receptor with a high expression in human placenta, particularly ERRγ1. ERRγ has been proposed to play a central role in controlling genes involved in energy metabolism. In placenta, ERRγ1 acts as an oxygen-responsive transcription factor regulating aromatase (Aro) expression during trophoblast differentiation. Aromatase is an enzyme that catalyzes the synthesis of estrogens from androgens and is located in the syncytiotrophoblast. An adequate estrogen-androgen balance is required for normal pregnancy progression. Our aim was to analyze ERRγ1 and Aro mRNA in human placenta from term LGA newborns. We propose that ERRγ1 and CYP19A1 expressions in human placenta from LGA newborns are impaired, which would modify fetal programming of LGA newborns, since an imbalance in intrauterine estrogen-androgen ratio would be occurred Methods: Total RNA was obtained from placental tissues of LGA (GA: 39-41 weeks, n=8) and adequate for gestational age (AGA; 39-40 weeks, n=10) newborns. ERRγ1 and Aro mRNA variants were analyzed by RT2-PCR. Primers for Aro analysis were specific for Total aromatase (TotalAro) binding in exons 2-3 and for Active aromatase (ActAro) in exons 9-10. Aro protein was analyzed by Western-blot.</p><p><strong>Results: </strong>ERRγ1 mRNA was significantly higher in LGA compare to AGA. TotalAro mRNA was significantly lower in LGA in comparison with AGA control. Similar results with Aro protein. In contrast ActAro/TotalAro ratio was higher in LGA compared to the AGA control.</p><p><strong>Conclusions: </strong>High expression of ERRγ1 as well as ActAro/TotalAro ratio in LGA suggests that ERRγ1 is involved in ActAro variant expression and hence disrupted estrogen-androgen balance in the intrauterine environment. We propose that dysregulation of ERRγ1 in placenta might modify the estrogen-androgen balance in the intrauterine environment in LGA newborns, possibly representing one of the key factors in the regulation of fetal programming.</p>","PeriodicalId":13025,"journal":{"name":"Hormone Research in Paediatrics","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140293397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Idiopathic Pathological Ketotic Hypoglycemia: Finding the Needle in a Haystack. 特发性病理性酮症低血糖:大海捞针。
IF 3.2 3区 医学 Q1 Medicine Pub Date : 2024-03-21 DOI: 10.1159/000538483
Joseph I Wolfsdorf, Terry G J Derks, Danielle Drachmann, Pratik Shah, Paul S Thornton, David A Weinstein

Sick children often have a decreased appetite and experience vomiting and diarrhea; however, hypoglycemia (plasma glucose concentration ≤50 mg/dL or 2.8 mmol/L) is rare. Ketotic hypoglycemia (KH) is the most common cause of hypoglycemia presenting to an Emergency Department in a previously healthy child between 6 months and 6 years of age. Ketosis and hypoglycemia are now well understood to be normal physiologic responses of young children to prolonged fasting.There is now substantial evidence that the term KH describes a variety of conditions including both the lower end of the normal distribution of fasting tolerance in young children as well as numerous rare disorders that impair fasting adaptation. Recent advances in molecular genetic testing have led to the discovery of these rare disorders. Idiopathic pathological KH is a diagnosis of exclusion that describes rare children who have abnormally limited fasting tolerance, experience recurrent episodes of KH, or develop symptoms of hypoglycemia despite elevated ketone levels, and in whom an explanation cannot be found despite extensive investigation. This review provides an approach to distinguishing between physiological KH and pathological KH and includes recommendations for management.

患病儿童通常食欲下降、呕吐和腹泻,但低血糖症(血浆葡萄糖浓度≤50 毫克/分升或 2.8 毫摩尔/升)却很少见。酮症性低血糖(KH)是以前健康的 6 个月至 6 岁儿童在急诊科出现低血糖的最常见原因。酮症酸中毒和低血糖是幼儿对长期禁食的正常生理反应,这一点现已得到充分理解。现在有大量证据表明,KH 一词可以描述多种情况,包括幼儿禁食耐受性正常分布的下限以及许多损害禁食适应性的罕见疾病。分子基因检测技术的最新进展导致了这些罕见疾病的发现。特发性病理性酮症酸中毒是一种排除性诊断,用于描述空腹耐量异常受限、酮症酸中毒反复发作或在酮体水平升高的情况下仍出现低血糖症状的罕见儿童。本综述提供了一种区分生理性酮症酸中毒和病理性酮症酸中毒的方法,并提出了处理建议。
{"title":"Idiopathic Pathological Ketotic Hypoglycemia: Finding the Needle in a Haystack.","authors":"Joseph I Wolfsdorf, Terry G J Derks, Danielle Drachmann, Pratik Shah, Paul S Thornton, David A Weinstein","doi":"10.1159/000538483","DOIUrl":"10.1159/000538483","url":null,"abstract":"<p><p>Sick children often have a decreased appetite and experience vomiting and diarrhea; however, hypoglycemia (plasma glucose concentration ≤50 mg/dL or 2.8 mmol/L) is rare. Ketotic hypoglycemia (KH) is the most common cause of hypoglycemia presenting to an Emergency Department in a previously healthy child between 6 months and 6 years of age. Ketosis and hypoglycemia are now well understood to be normal physiologic responses of young children to prolonged fasting.There is now substantial evidence that the term KH describes a variety of conditions including both the lower end of the normal distribution of fasting tolerance in young children as well as numerous rare disorders that impair fasting adaptation. Recent advances in molecular genetic testing have led to the discovery of these rare disorders. Idiopathic pathological KH is a diagnosis of exclusion that describes rare children who have abnormally limited fasting tolerance, experience recurrent episodes of KH, or develop symptoms of hypoglycemia despite elevated ketone levels, and in whom an explanation cannot be found despite extensive investigation. This review provides an approach to distinguishing between physiological KH and pathological KH and includes recommendations for management.</p>","PeriodicalId":13025,"journal":{"name":"Hormone Research in Paediatrics","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140184314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Hormone Research in Paediatrics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1